For many years researchers have been looking at the Th2 pathway to decrease the asthma inflammatory response.
Blocking the effects of the IL-13 pathway is being further explored. Results are promising and similar to anti-IgE anit allergen studies and superior to IL-5. Whether or not this leads to superior treatments than currently available treatments remain to be seen. But there is promising results for asthma patients. With the trend to individual treatment for asthmatic patients, it would be beneficial to have more available medications on the market as some patients may respond to one more than another. Asthma is a heterogenous disorder with many pathways involved and some patients will get more benefit from a differents set of treatment plans.